



BioXcel Begins Strategic Collaboration with Alnylam to Discover Novel RNAi Therapeutic Products

May 24, 2016

Partnership to Harness the Power of BioXcel's Big Data Innovation Lab

BRANFORD, Conn., May 24, 2016 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in real-time big data platforms for the discovery and development of transformative patient treatments, today announced the initiation of a strategic collaboration with Alnylam Pharmaceuticals to discover novel RNA interference (RNAi) therapeutic products. Alnylam is focused on developing and commercializing RNAi therapeutics - a new class of innovative medicines - with a focus on genetically defined targets for the treatment of serious diseases.

Alnylam will leverage BioXcel's Big Data Innovation Lab* (BDI-Lab) – by integrating the product discovery engine that will apply big data algorithms, recursive mapping and network pharmacology in conjunction with therapeutic expertise to build product blueprints for novel RNAi therapeutic products with a high probability of clinical and commercial success.

"We are pleased to join forces with Alnylam and leverage two disruptive platforms to create a portfolio of RNAi products for rare and common diseases. As we continue to collaborate with leading innovative biopharmaceutical companies across the spectrum of therapeutic modalities including RNAi, mRNA, gene therapy, gene editing, amino acid and cell based therapies, we hope to impact patients' lives by providing novel treatment options," **said Krishnan Nandabalan, Ph.D., BioXcel's President and Chief Scientific Officer.**

Under the terms of the agreement, BioXcel will be eligible to receive upfront and development milestone related payments from Alnylam. Financial terms of the agreement were not disclosed.

*Big Data Innovation Lab (BDI-Lab)

BDI-Lab is a first-of-its-kind ecosystem that identifies novel therapeutic candidates with a high probability of clinical and commercial success. The Lab supports any therapeutic area and modality ranging from small molecules to biologics, cellular- and nucleic acid-based therapies and is accessible to the biopharmaceutical industry through strategic partnerships.

The Lab has been built on decades of research and algorithm-based analytics with its core consisting of PharmGPS®, a real-time, predictive, cognitive intelligence platform for designing, strategizing, developing, and commercializing the next breakthrough treatments; a large Center of multi-disciplinary teams with deep domain expertise, to unlock the therapeutic value of technology platforms and pipeline assets; and a highly experienced and therapeutically aligned drug development team whose expertise spans all stages of development across any major therapeutic area or rare disease, to generate drug candidates.

About BioXcel

BioXcel Corporation is a next generation biotechnology company dedicated to improving the probability of the clinical and commercial success of drugs by applying big data analytics. Using a network based pharmacology approach our first in class Big Data Innovation Lab has generated a clinical pipeline focused on immuno-oncology and CNS orphan diseases representing a new paradigm for deciphering therapeutic value. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA.

Contact:

BioXcel Corporation

Anita Ganjoo

Corporate Communications

Email: aganjoo@bioxcel.com

Tel: 203 957 2487

Source: BioXcel Corporation